Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.S. with Honors, University of Wisconsin-Madison (2000)

M.D. with Honors in Research, University of Wisconsin School of Medicine & Public Health (2007)

Residency in Internal Medicine, University of Wisconsin Hospital & Clinics (2007-2010)

Fellowship in Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center (2010-2013)

Ryan Cassaday, MD
Assistant Professor, Division of Hematology
University of Washington School of Medicine

Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center

Attending Physician, Hematologic Malignancies Program
Seattle Cancer Care Alliance
Office Address:
Seattle Cancer Care Alliance
825 Eastlake Ave E, Box 358081, Mailstop G3200
Seattle, WA 98109

Phone:        (206) 288-6744
Fax:              (206) 288-1130
E-mail:         cassaday@u.washington.edu


Acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma


Testing novel treatments and developing improved risk-stratification methods for adults with acute lymphoblastic leukemia and high-risk lymphoma.


I am a clinical investigator interested primarily in improving the treatment of adults with acute lymphoblastic leukemia (ALL) as well as aggressive lymphomas. My main focus is on the development and conduct of prospective clinical trials testing novel approaches to the treatment of these diseases. I also use clinical databases for retrospective analyses to make inferences and inform decisions regarding current patient care and future clinical trials. Though I do not have a laboratory, I collaborate with colleagues who do.


Cassaday RD, Guthrie KA, Budde LE, et al. Specific features identify patients with relapsed/refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 19(9):1403-6; Sept 2013.

Petrich AM, Gandhi M, Jovanovic B, ... Cassaday RD, Li S, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. Blood. 2014 Oct 9;124(15):2354-61.

Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ, Rezvani AR, Storb RF, Press OW, Gopal AK. Long-term outcomes of patients with persistent indolent B-cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant. 2015 Feb;21(2):281-7.

Cassaday RD, Goy A, Advani S, et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):392-7.

Cassaday RD, Stevenson PA, Gooley TA, et al. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol. 2015 Dec;171(5):788-97.

Cassaday RD, Potts DA, Stevenson PA, et al. Evaluation of allogeneic transplantation in first or later minimal residual disease-negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016 Sep;57(9):2109-18.